z-logo
open-access-imgOpen Access
Liraglutide administration in type 2 diabetic patients who either received no previous treatment or were treated with an oral hypoglycemic agent showed greater efficacy than that in patients switching from insulin
Author(s) -
Nambu Takuo,
Matsuda Yuki,
Matsuo Koji,
Kanai Yugo,
Yonemitsu Shin,
Muro Seiji,
Oki Shogo
Publication year - 2013
Publication title -
journal of diabetes investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.089
H-Index - 50
eISSN - 2040-1124
pISSN - 2040-1116
DOI - 10.1111/j.2040-1124.2012.00242.x
Subject(s) - liraglutide , medicine , glycated hemoglobin , type 2 diabetes , insulin , glycemic , diabetes mellitus , endocrinology , insulin analog , glucagon like peptide 1 receptor , oral administration , glucagon like peptide 1 , agonist , receptor , human insulin
Aims/Introduction Liraglutide, a glucagon‐like peptide‐1 receptor agonist, is expected to provide a new treatment option for diabetes. However, the suitable timing of liraglutide administration in type 2 diabetic patients has not yet been clarified. Materials and Methods We reviewed type 2 diabetic patients ( n  = 155) who visited the O saka R ed C ross H ospital for glycemic control, with administration of liraglutide at a dose of 0.6 mg (average glycated hemoglobin [ H b A 1c ] level, 8.7 ± 0.1%). The effect of liraglutide based on the pretreatment status was compared. We also analyzed the background factors of both a successful and failed group of patients who switched to liraglutide from insulin. Results An improvement in blood glucose levels was confirmed in 122 of 155 patients. During the 4‐month observation period, the improvement in H b A 1c levels was significantly greater in the group of drug‐naïve/previous oral hypoglycemic agent (9.1 ± 0.2 to 7.2 ± 0.2%) than that in the group switching from insulin (8.6 ± 0.2 to 7.8 ± 0.2%). In addition, C ‐peptide immunoreactivity levels (fasting > 2.2 ng/mL; delta >1.6 ng/mL; urine > 70 μg/day), younger age and a smaller number of insulin units used per day were considered important when deciding on switching to liraglutide from insulin. Conclusions Liraglutide was more effective in patients who had not been treated previously or received oral hypoglycemic agents than in patients switching from insulin. With respect to switching to liraglutide from insulin, the most important factors to be considered were C ‐peptide immunoreactivity levels, age, and the number of insulin units used per day.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here